Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Hematology/Oncology Clinics of North America

Volumn 23, Issue 5, 2009, Pages 1043-1063

  Ravandi, Farhad ^a   Kebriaei, Partow ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Allogeneic stem cell transplant; BCR ABL; Philadelphia chromosome; Tyrosine kinase inhibition

Indexed keywords

ADENOSINE TRIPHOSPHATE; AP 24534; ASPARAGINASE; BCR ABL PROTEIN; BOSUTINIB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DASATINIB; DAUNORUBICIN; DCC 2036; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HOMOHARRINGTONINE; IMATINIB; METHOTREXATE; MITOXANTRONE; NILOTINIB; PHA 739358; PLERIXAFOR; PREDNISOLONE; PREDNISONE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VINCRISTINE; XL 228;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER INHIBITION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BRAIN LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERBILIRUBINEMIA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; HUMANS; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 70349754444     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.07.007     Document Type: Review

References (111)

1. Nowell P.C., and Hungerford D.A. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 25 (1960) 85-109
2. Rowley J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (1973) 290-293
3. Daley G.Q., Van Etten R.A., and Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247 (1990) 824-830
4. Schlieben S., Borkhardt A., Reinisch I., et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia 10 (1996) 957-963
5. Hoelzer D. Advances in the management of Ph-positive ALL. Clin Adv Hematol Oncol 4 (2006) 804-805
6. Kantarjian H.M., Talpaz M., Dhingra K., et al. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood 78 (1991) 2411-2418
7. Li S., Ilaria Jr. R.L., Million R.P., et al. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 189 (1999) 1399-1412
8. Gleissner B., Gokbuget N., Bartram C.R., et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99 (2002) 1536-1543
9. Arico M., Valsecchi M.G., Camitta B., et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342 (2000) 998-1006
10. Schrappe M., Arico M., Harbott J., et al. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 92 (1998) 2730-2741
11. Radich J.P. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 15 (2001) 21-36
12. Larson R.A. Management of acute lymphoblastic leukemia in older patients. Semin Hematol 43 (2006) 126-133
13. Pane F., Cimino G., Izzo B., et al. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia 19 (2005) 628-635
14. Garcia-Manero G., and Thomas D.A. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am 15 (2001) 163-205
15. Thomas D.A., Faderl S., Cortes J., et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103 (2004) 4396-4407
16. Yanada M., Takeuchi J., Sugiura I., et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24 (2006) 460-466
17. Schultz K.R., Bowman W.P., Slayton W., et al. Improved early event free survival (EFS) in children with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with intensive Imatinib in combination with high dose chemotherapy: Children's Oncology Group (COG) Study AALL0031. Blood 110 (2007) [Abstract #4]
18. Druker B.J., Sawyers C.L., Kantarjian H., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344 (2001) 1038-1042
19. Ottmann O.G., Druker B.J., Sawyers C.L., et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100 (2002) 1965-1971
20. Champagne M.A., Capdeville R., Krailo M., et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood 104 (2004) 2655-2660
21. Scheuring U.J., Pfeifer H., Wassmann B., et al. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). Blood 101 (2003) 85-90
22. Wassmann B., Pfeifer H., Scheuring U.J., et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treated with imatinib. Blood 103 (2004) 1495-1498
23. Thiesing J.T., Ohno-Jones S., Kolibaba K.S., et al. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 96 (2000) 3195-3199
24. Kano Y., Akutsu M., Tsunoda S., et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97 (2001) 1999-2007
25. Topaly J., Zeller W.J., and Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 15 (2001) 342-347
26. Thomas D.A., Kantarjian H.M., Cortes J., et al. Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia Chromosome (Ph) positive acute lymphoblastic leukemia (ALL). Blood 112 (2008) [Abstract #2931]
27. Lee K.H., Lee J.H., Choi S.J., et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 19 (2005) 1509-1516
28. Towatari M., Yanada M., Usui N., et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 104 (2004) 3507-3512
29. Wassmann B., Pfeifer H., Goekbuget N., et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 108 (2006) 1469-1477
30. de Labarthe A., Rousselot P., Huguet-Rigal F., et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 109 (2007) 1408-1413
31. Dombret H., Gabert J., Boiron J.M., et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood 100 (2002) 2357-2366
32. Vignetti M., Fazi P., Cimino G., et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 109 (2007) 3676-3678
33. Delannoy A., Delabesse E., Lheritier V., et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 20 (2006) 1526-1532
34. Ottmann O.G., Wassmann B., Pfeifer H., et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Cancer 109 (2007) 2068-2076
35. Laport G.G., Alvarnas J.C., Palmer J.M., et al. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood 112 (2008) 903-909
36. Champlin R.E., Schmitz N., Horowitz M.M., et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 95 (2000) 3702-3709
37. Schmitz N., Beksac M., Hasenclever D., et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 100 (2002) 761-767
38. Fielding A.K., Rowe J.M., Richards S.M., et al. Prospective outcome data on 267 unselected adult patients with Philadelphia-chromosome positive acute lymphoblastic leukaemia confirms superiority of allogeneic transplant over chemotherapy in the pre-imatinib era: Results from the international ALL trial MRC UKALLXII/ECOG2993. Blood 113 (2009) 4489-4496
39. Thiebaut A., Vernant J.P., Degos L., et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 14 (2000) 1353-1366 x
40. Krejci O., van der Velden V.H., Bader P., et al. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group. Bone Marrow Transplant 32 (2003) 849-851
41. Goulden N., Bader P., Van Der Velden V., et al. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol 122 (2003) 24-29
42. Lee S., Kim D.W., Kim Y.J., et al. Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 102 (2003) 3068-3070
43. Lee S., Kim Y.J., Min C.K., et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 105 (2005) 3449-3457
44. Shimoni A., Kroger N., Zander A.R., et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 17 (2003) 290-297
45. Radich J., Gehly G., Lee A., et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 89 (1997) 2602-2609
46. Anderlini P., Sheth S., Hicks K., et al. Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Transplant 10 (2004) 883-884
47. Wassmann B., Pfeifer H., Stadler M., et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 106 (2005) 458-463
48. Carpenter P.A., Snyder D.S., Flowers M.E., et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 109 (2007) 2791-2793
49. Visani G., Isidori A., Malagola M., et al. Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190(BCR-ABL)-positive acute lymphoblastic leukemia. Leukemia 16 (2002) 2159-2160
50. Wassmann B., Scheuring U., Pfeifer H., et al. Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Leukemia 17 (2003) 1919-1924
51. Martino R., Giralt S., Caballero M.D., et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica 88 (2003) 555-560
52. Sullivan K.M., Weiden P.L., Storb R., et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73 (1989) 1720-1728
53. Doney K., Fisher L.D., Appelbaum F.R., et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant 7 (1991) 453-459
54. Cornelissen J.J., Carston M., Kollman C., et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 97 (2001) 1572-1577
55. Terwey T.H., Massenkeil G., Tamm I., et al. Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy. Bone Marrow Transplant 42 (2008) 791-798
56. Fielding A.K., Richards S.M., Chopra R., et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109 (2007) 944-950
57. Biggs J.C., Horowitz M.M., Gale R.P., et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 80 (1992) 1090-1093
58. Forman S.J., Schmidt G.M., Nademanee A.P., et al. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. J Clin Oncol 9 (1991) 1570-1574
59. Grigg A.P., Szer J., Beresford J., et al. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. Br J Haematol 107 (1999) 409-418
60. Marks D.I., Aversa F., and Lazarus H.M. Alternative donor transplants for adult acute lymphoblastic leukaemia: a comparison of the three major options. Bone Marrow Transplant 38 (2006) 467-475
61. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
62. Shah N.P., Nicoll J.M., Nagar B., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
63. Burger H., van Tol H., Boersma A.W., et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104 (2004) 2940-2942
64. Thomas J., Wang L., Clark R.E., et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104 (2004) 3739-3745
65. Donato N.J., Wu J.Y., Stapley J., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101 (2003) 690-698
66. White D.L., Saunders V.A., Dang P., et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108 (2006) 697-704
67. White D.L., Saunders V.A., Dang P., et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110 (2007) 4064-4072
68. Corbin A.S., La Rosee P., Stoffregen E.P., et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101 (2003) 4611-4614
69. Hochhaus A., Kreil S., Corbin A.S., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16 (2002) 2190-2196
70. Jabbour E., Kantarjian H., Jones D., et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20 (2006) 1767-1773
71. Hofmann W.K., Jones L.C., Lemp N.A., et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99 (2002) 1860-1862
72. von Bubnoff N., Schneller F., Peschel C., et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359 (2002) 487-491
73. Hofmann W.K., Komor M., Wassmann B., et al. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 102 (2003) 659-661
74. Pfeifer H., Wassmann B., Pavlova A., et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 110 (2007) 727-734
75. Jones D., Thomas D., Yin C.C., et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 113 (2008) 985-994
76. Soverini S., Colarossi S., Gnani A., et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 12 (2006) 7374-7379
77. Iacobucci I., Lonetti A., Messa F., et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood 112 (2008) 3847-3855
78. Cobb B.S., and Smale S.T. Ikaros-family proteins: in search of molecular functions during lymphocyte development. Curr Top Microbiol Immunol 290 (2005) 29-47
79. Mishra S., Zhang B., Cunnick J.M., et al. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells. Cancer Res 66 (2006) 5387-5393
80. Shah N.P., Tran C., Lee F.Y., et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
81. Talpaz M., Shah N.P., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354 (2006) 2531-2541
82. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354 (2006) 2542-2551
83. Brown V.I., Seif A.E., Reid G.S., et al. Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. Immunol Res 42 (2008) 84-105
84. Cortes J., Rousselot P., Kim D.W., et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109 (2007) 3207-3213
85. Ottmann O., Dombret H., Martinelli G., et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110 (2007) 2309-2315
86. Larson R.A., Ottmann O.G., Shah N.P., et al. Dasatinib 140 mg once daily (QD) has equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with imatinib-resistant or -Intolerant Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): 2-year data from CA180-035. Blood 112 (2008) [Abstract #2926]
87. Jabbour E., O'Brien S., Thomas D., et al. Combination of the hyperCVAD regimen with dasatinib is effective in patients with relapsed Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB). Blood 112 (2008) [Abstract #2919]
88. Ravandi F., Thomas D., Kantarjian H., et al. Phase II study of combination of hyperCVAD with dasatinib in frontline therapy of patients with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL). Blood 112 (2008) [Abstract #2921]
89. ®) and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL: Results of the first 22 patients Included in the EWALL-Ph-01 trial (on behalf of the European Working Group on Adult ALL (EWALL)). Blood 112 (2008) [Abstract #2920]
90. Foà R., Vitale A., Guarini A., et al. Line treatment of adult Ph+ acute lymphoblastic leukemia (ALL) patients. Final results of the GIMEMA LAL1205 study. [abstract]. Blood 112 (2008)
91. Soverini S., Martinelli G., Colarossi S., et al. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol 24 (2006) e51-e52
92. Tokarski J.S., Newitt J.A., Chang C.Y., et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66 (2006) 5790-5797
93. O'Hare T., Walters D.K., Stoffregen E.P., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65 (2005) 4500-4505
94. Cortes J. Central nervous system involvement in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 15 (2001) 145-162
95. Lazarus H.M., Richards S.M., Chopra R., et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood 108 (2006) 465-472
96. Pfeifer H., Wassmann B., Hofmann W.K., et al. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res 9 (2003) 4674-4681
97. Leis J.F., Stepan D.E., Curtin P.T., et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma 45 (2004) 695-698
98. Takayama N., Sato N., O'Brien S.G., et al. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 119 (2002) 106-108
99. Porkka K., Koskenvesa P., Lundan T., et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 112 (2008) 1005-1012
100. Bloomfield C.D., Goldman A.I., Alimena G., et al. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood 67 (1986) 415-420
101. Gotz G., Weh H.J., Walter T.A., et al. Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia. Ann Hematol 64 (1992) 97-100
102. Larson R.A., Dodge R.K., Burns C.P., et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 85 (1995) 2025-2037
103. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A collaborative study of the Groupe Francais de Cytogenetique Hematologique. Blood 87 (1996) 3135-3142
104. Secker-Walker L.M., Prentice H.G., Durrant J., et al. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol 96 (1997) 601-610
105. Wetzler M., Dodge R.K., Mrozek K., et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood 93 (1999) 3983-3993
106. Faderl S., Kantarjian H.M., Thomas D.A., et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 36 (2000) 263-273
107. Mahon F.X., Belloc F., Lagarde V., et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101 (2003) 2368-2373
108. Crossman L.C., Druker B.J., Deininger M.W., et al. hOCT 1 and resistance to imatinib. Blood 106 (2005) 1133-1134 author reply 1134
109. Gambacorti-Passerini C., Barni R., le Coutre P., et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92 (2000) 1641-1650
110. Wendel H.G., de Stanchina E., Cepero E., et al. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci U S A 103 (2006) 7444-7449
111. Graham S.M., Jorgensen H.G., Allan E., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99 (2002) 319-325